MedTrace Logo

A Study of KW-3357 in Congenital Antithrombin Deficiency

NCT00938288 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-10-17

No results posted yet for this study

Summary

The aim of this study is to determine the pharmacokinetics, safety and tolerability of KW-3357 in asymptomatic subjects with congenital antithrombin deficiency.

Conditions

  • Congenital Antithrombin Deficiency

Interventions

DRUG

KW-3357

50IU/mL, IV single dose

Sponsors & Collaborators

  • Kyowa Hakko Kirin UK, Ltd.

    collaborator INDUSTRY

  • Kyowa Kirin Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Beverley Hunt, FRCP, FRCPath MD · St Thomas' Hospital, London, UK

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-12-22
Completion
2011-04-30

Countries

  • Germany
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00938288 on ClinicalTrials.gov